A US report has highlighted a worrying increase in obesity-related cancer deaths and warns that more cases may be diagnosed at a later stage due to disruptions caused by the COVID-19 pandemic.

A new long-term study has confirmed that once-weekly doses of tirzepatide (branded as Mounjaro) can deliver significant and sustained weight loss for up to three years in adults living with overweight or obesity who do not have diabetes.

The United States could see one of the sharpest drops in obesity rates globally, thanks to the growing use of weight loss drugs such as Ozempic and Wegovy, according to a new report.

Medications used to treat obesity and type 2 diabetes — particularly semaglutides such as Ozempic and Wegovy — may reduce the risk of dementia, according to new research.

A new study has turned a long-standing belief about cardiovascular disease on its head. Rather than being caused by a build-up of fat molecules called ceramides, researchers have found that in obesity and diabetes, it’s actually the decrease of these fats in blood vessels that may lead to health problems.

Marriage may bring love and companionship, but it also appears to come with a greater risk of obesity — especially for men. A new study suggests that men who are married are 3.2 times more likely to become obese compared to their unmarried counterparts.

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) has revealed that a new diagnosis of type 2 diabetes is associated with an increased risk of developing certain obesity-related cancers. However, the study found that this link does not apply to all obesity-related cancers.

New research published in Nature reveals that chronic exposure to high-fat diets diminishes the brain's reward response to food, reducing the pleasure associated with eating.

The NHS has released interim commissioning guidance to support the implementation of the NICE Technology Appraisal (NICE TA1026) and the NICE Funding Variation for tirzepatide (Mounjaro®) in the management of obesity.

New research set to be presented at the European Congress on Obesity (ECO 2025) in Malaga, Spain (11-14 May) reveals that children who are living with overweight or obesity face a significantly higher risk of developing chronic obstructive pulmonary disease (COPD) in adulthood.

Novo Nordisk presented new data from the retrospective, observational SCORE study that assessed treatment with Wegovy® (semaglutide injection) 2.4 mg and the risk of major adverse cardiovascular events (MACE) in adults living with overweight or obesity and established cardiovascular disease (CVD).

Novo Nordisk today presented full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (semaglutide tablets, 14mg) significantly reduced the risk of major adverse cardiovascular events in adults living with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

Novo Nordisk has secured global rights to China-based United Laboratories International's experimental weight-loss drug, UBT251, in a deal worth up to $2 billion.

A new study has found that planned non-labour caesarean section (NLCS) is associated with a reduced risk of complications in pregnant women living with obesity compared to spontaneous labour.

A new study has found that extreme weight fluctuations — both gain and loss — significantly increase the risk of death in individuals living with obesity and cardiovascular disease.

A new study has highlighted a concerning connection between obesity, high stress levels, and pancreatic cancer — one of the deadliest forms of the disease.

Zealand Pharma has officially partnered with Roche to develop and commercialise its lead obesity treatment candidate, petrelintide, marking a major milestone in the company’s obesity drug pipeline.

New research from the University of Cambridge has identified a genetic link between obesity in humans and Labrador Retrievers, shedding light on the fundamental biology of weight gain.

Novo Nordisk has announced promising results from the REDEFINE 2 trial, a pivotal phase 3 study investigating the efficacy and safety of CagriSema in people living with obesity or overweight and type 2 diabetes.

A new study has found that GLP-1 receptor agonists, may significantly benefit kidney transplant recipients with type 2 diabetes. The research, published in The Lancet Diabetes and Endocrinology, suggests that these medications reduce the risk of organ failure and improve survival rates in transplant patients.